Biotech entity
Every one of those 1 sits in a single category, pharma. IB-Stim is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. IB-Stim is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window. Each story carries 3 original sources on average, compared with 2.8 for the broader beat in this window. NeurAxis, Inc. appears in 1 tracked Biotech story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NeurAxis, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Expected top-line data from Phase 3 adjunctive MDD trials.
Earnings Call
CEO Sergio Traversa provides update on Reliance II and Reliance III trials.
Enrollment Completion
Anticipated completion of enrollment for the pivotal Reliance II study.
Q4 2025 Close
Relmada concludes fiscal year with focus on Phase 3 enrollment.
Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its pivotal trials while maintaining a strategic cash position to reach key clinical milestones.
NeurAxis, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
